Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Accuray ( (ARAY) ).
On February 17, 2026, Accuray Incorporated posted an updated investor presentation on its investor relations website and made the materials available as an exhibit for reference. Company spokespeople indicated they would use the updated presentation in discussions with analysts and investors on or after that date, positioning the deck as summary information meant to be read alongside Accuray’s existing U.S. Securities and Exchange Commission filings and prior public disclosures. The company emphasized that the furnished materials are not deemed filed for purposes of securities law liability and do not create an obligation for Accuray to update the information, framing the release primarily as a routine investor communication rather than a signal of new material developments.
The most recent analyst rating on (ARAY) stock is a Hold with a $0.52 price target. To see the full list of analyst forecasts on Accuray stock, see the ARAY Stock Forecast page.
Spark’s Take on ARAY Stock
According to Spark, TipRanks’ AI Analyst, ARAY is a Underperform.
The score is driven down primarily by weak financial performance (losses, declining revenue, and high leverage with a thin equity cushion) and strongly bearish technicals (below all major moving averages with negative momentum). Valuation offers limited support due to negative earnings and no dividend, while the latest earnings call adds further pressure via lowered guidance and margin/cash deterioration despite some demand and restructuring positives.
To see Spark’s full report on ARAY stock, click here.
More about Accuray
Accuray Incorporated operates in the medical technology industry, specializing in radiation therapy systems used for cancer treatment and other medical conditions. The company focuses on advanced precision radiotherapy solutions sold primarily to hospitals and cancer centers in global healthcare markets, supporting clinicians with tools for targeted, image-guided treatments.
Average Trading Volume: 1,056,593
Technical Sentiment Signal: Sell
Current Market Cap: $62.07M
See more insights into ARAY stock on TipRanks’ Stock Analysis page.